Hip
Senior Member
- Messages
- 18,161
Dr John Chia, the late Dr John Richardson and others maintain the view that enteroviruses such as coxsackievirus B are responsible for most cases of ME/CFS.
Thus if there were an effective vaccine for coxsackievirus B, this may well drastically reduce the incidence of ME/CFS in future.
Looking around on PubMed for evidence of any success in developing a coxsackievirus B vaccine, it seems that there have been a some effective attempts. Thus a coxsackievirus B vaccine appears feasible.
The question is, why hasn't such a vaccine been introduced, when it could help prevent one of the worst diseases known to man (in terms of reduced quality of life)?
Here are the details of some successful experimental attempts in developing and testing a coxsackievirus B vaccine:
In this study: A Vaccine to Coxsackievirus Prepared by High Pressure, it says:
In this study: High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis, it says:
In this study: Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis, it says:
In this study: Vaccination procedures against Coxsackievirus-induced heart disease, it says:
This study: Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines discusses the problems to be overcome in the development of live-attenuated vaccines. (But I don't have access to the full paper).
Thus if there were an effective vaccine for coxsackievirus B, this may well drastically reduce the incidence of ME/CFS in future.
Looking around on PubMed for evidence of any success in developing a coxsackievirus B vaccine, it seems that there have been a some effective attempts. Thus a coxsackievirus B vaccine appears feasible.
The question is, why hasn't such a vaccine been introduced, when it could help prevent one of the worst diseases known to man (in terms of reduced quality of life)?
Here are the details of some successful experimental attempts in developing and testing a coxsackievirus B vaccine:
In this study: A Vaccine to Coxsackievirus Prepared by High Pressure, it says:
"using different murine model systems it has been demonstrated that classic as well as newly developed vaccination procedures are quite successful in preventing Coxsackievirus B3 infections."
In this study: High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis, it says:
"we have shown that vaccine can be made against Coxsackie B3 virus with good protective effect and significant neutralisation antibody titre."
In this study: Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis, it says:
"These results demonstrate that CVB3 capsid proteins expressed in insect cells have the intrinsic capacity to assemble into non-infectious VLP, which afforded protection from CVB3 infection to mice when used as a vaccine."
In this study: Vaccination procedures against Coxsackievirus-induced heart disease, it says:
"using different murine model systems it has been demonstrated that classic as well as newly developed vaccination procedures are quite successful in preventing Coxsackievirus B3 infections. In particular, the application of an interferon-gamma-expressing recombinant Coxsackievirus variant against Coxsackievirus B3-induced myocarditis has been effective."
This study: Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines discusses the problems to be overcome in the development of live-attenuated vaccines. (But I don't have access to the full paper).
Last edited: